Larimar Therapeutics, Inc. (NASDAQ:LRMR – Get Rating) – Equities research analysts at William Blair issued their Q1 2025 earnings per share (EPS) estimates for Larimar Therapeutics in a report released on Tuesday, May 16th. William Blair analyst M. Minter forecasts that the company will earn ($0.22) per share for the quarter. The consensus estimate for […]
Larimar Therapeutics, Inc. (NASDAQ:LRMR – Get Rating) Director Joseph Truitt purchased 2,750 shares of the stock in a transaction on Wednesday, May 17th. The stock was acquired at an average cost of $3.73 per share, for a total transaction of $10,257.50. Following the completion of the acquisition, the director now owns 2,750 shares of the […]
Larimar Therapeutics, Inc. (NASDAQ:LRMR – Get Rating) CFO Michael Celano purchased 5,000 shares of the stock in a transaction dated Wednesday, May 17th. The stock was bought at an average cost of $3.73 per share, with a total value of $18,650.00. Following the completion of the purchase, the chief financial officer now owns 112,746 shares […]
Larimar Therapeutics (NASDAQ:LRMR – Get Rating) had its target price increased by Guggenheim from $12.00 to $14.00 in a research note released on Wednesday morning, The Fly reports. Larimar Therapeutics Stock Performance Shares of NASDAQ LRMR remained flat at $3.69 during trading hours on Wednesday. The company had a trading volume of 849,576 shares, compared […]
Larimar Therapeutics, Inc. (NASDAQ:LRMR – Get Rating) Director Joseph Truitt purchased 2,750 shares of the business’s stock in a transaction on Wednesday, May 17th. The stock was acquired at an average price of $3.73 per share, with a total value of $10,257.50. Following the purchase, the director now directly owns 2,750 shares in the company, […]